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Introduction-—HIV infection and certain antiretroviral therapy (ART) medications increase atherosclerotic cardiovascular disease
risk, mediated, in part, through traditional cardiovascular disease risk factors.
Methods and Results-—We studied cardiovascular disease risk factor changes in the START (Strategic Timing of Antiretroviral
Treatment) trial, a randomized study of immediate versus deferred ART initiation among HIV-positive persons with CD4+ cell counts
>500 cells/mm3. Mean change from baseline in risk factors and the incidence of comorbid conditions were compared between
groups. The characteristics among 4685 HIV-positive START trial participants include a median age of 36 years, a CD4 cell count of
651 cells/mm3, an HIV viral load of 12 759 copies/mL, a current smoking status of 32%, a median systolic/diastolic blood
pressure of 120/76 mm Hg, and median levels of total cholesterol of 168 mg/dL, low-density lipoprotein cholesterol of 102 mg/
dL, and high-density lipoprotein cholesterol of 41 mg/dL. Mean follow-up was 3.0 years. The immediate and deferred ART groups
spent 94% and 28% of follow-up time taking ART, respectively. Compared with patients in the deferral group, patients in the
immediate ART group had increased total cholesterol and low-density lipoprotein cholesterol and higher use of lipid-lowering
therapy (1.2%; 95% CI, 0.1–2.2). Concurrent increases in high-density lipoprotein cholesterol with immediate ART resulted in a 0.1
lower total cholesterol to high-density lipoprotein cholesterol ratio (95% CI, 0.1–0.2). Immediate ART resulted in 2.3% less
BP-lowering therapy use (95% CI, 0.9–3.6), but there were no differences in new-onset hypertension or diabetes mellitus.
Conclusions-—Among HIV-positive persons with preserved immunity, immediate ART led to increases in total cholesterol and low-
density lipoprotein cholesterol but also concurrent increases in high-density lipoprotein cholesterol and decreased use of blood
pressure medications. These opposing effects suggest that, in the short term, the net effect of early ART on traditional
cardiovascular disease risk factors may be clinically insigniﬁcant."
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H IV-positive persons are at increased risk for prematurecardiovascular disease (CVD),1 which is currently a
leading cause of morbidity and mortality.2 Atherosclerotic
disease accounts for a substantial proportion of HIV-related
CVD among contemporary patients. This atherosclerotic dis-
ease manifests as excess risk for coronary heart disease (CHD;
eg, myocardial infarction)1 and stroke,3 andmay also contribute
to excess risk for heart failure4 and sudden cardiac death.5
It is well established that features of both HIV infection and
certain antiretroviral medications increase the risk for CVD.
Some of this excess CVD risk may be caused by long-term
systemic inﬂammation that ismitigated, in part, via antiretroviral
therapy (ART)–associated viral suppression,6–9 whereas some
may be caused by exposure to speciﬁc antiretrovirals (eg,
certain protease inhibitors [PIs] and abacavir)10 with potential
for adverse changes in blood cholesterol, platelet dysfunction,
and/or endothelial dysfunction.10–13 Despite unique features of
HIV disease, traditional risk factors are highly predictive for CVD
amongHIV-positive patients1,10,14 and canbe adversely affected
by HIV infection and ART treatment (eg, dyslipidemia).15
Given the potential for ART to both increase (via drug toxicity
and low-density lipoprotein cholesterol [LDL-C] increases) and
decrease (via viral suppression and reduced inﬂammation)
atherosclerosis, it is important to study this pathophysiology in
the context of randomized comparisons. The START (Strategic
Timing of Antiretroviral Treatment) trial is a randomized
controlled study of immediate initiation of ART (“immediate”
group) versus deferral of ART initiation until CD4+ cell counts
decline to <350 cells/mm3 or clinical symptoms develop
(“deferred” group) among participants naive to ART with CD4+
cell counts >500 cells/mm3 at entry.16 The START trial used an
ideal design to compare CVD risk factors between ART-treated
and untreated HIV infection in a controlled fashion among
persons at low risk for AIDS. CVD events were a component of
the composite end point in the START trial, and participants with
a recent CVD event (<6 months from entry) were not eligible.
The START trial did not have sufﬁcient power to speciﬁcally
assess CVD event risk (12 and 14 CVD events in the immediate
and deferred groups, respectively).16 In this study, we charac-
terized the inﬂuence of immediate versus deferred ART on CVD
risk factor changes and incidence of CVD-related comorbidities.
Methods
Study Design and Data Collection
The design and primary ﬁndings from the START trial have
been described.16,17 The START protocol was approved by the
human subjects institutional review committee at the Univer-
sity of Minnesota and at all international coordinating centers
and participating clinical sites. After informed consent was
obtained, data collection occurred at baseline, months 1 and
4, and every 4 months thereafter. Participants were
instructed to fast (minimum of 8 hours) for annual blood
draws. Laboratory measures were performed using standard-
ized clinical assays at the sites. HIV RNA level, CD4+ cell
count, weight, and blood pressure (BP) were ascertained at
every study visit. The BP values used in the analyses were the
average of 2 measurements separated by a brief rest. Glucose
and serum lipid levels (total cholesterol, high-density lipopro-
tein cholesterol [HDL-C], LDL-C, and triglycerides) and
concomitant medication use were obtained at baseline and
annually. At screening, clinicians together with participants
prespeciﬁed the intended ART regimen a participant would
initiate if randomized to the immediate group. This regimen
was required to include 2 background nucleoside reverse
transcriptase inhibitors plus either a non-nucleoside reverse
transcriptase inhibitor (NNRTI) or a ritonavir-boosted PI, or an
integrase strand transfer inhibitor (INSTI). Deﬁning subgroups
by the prespeciﬁed ART regimen allowed a randomized
comparison between the immediate and deferred groups
among those who were designated to start the same
antiretroviral medication. Data for this report included visits
up to the START trial unblinding date of May 26, 2015.
Clinical Comorbidities and Risk Factor Scores
Dyslipidemia was deﬁned as an LDL-C level ≥160 mg/dL or
use of lipid-lowering therapy. Hypertension was deﬁned as a
systolic BP ≥140 mm Hg, a diastolic BP ≥90 mm Hg, or use
of BP-lowering therapy. Diabetes mellitus was deﬁned as a
fasting glucose level >126 mg/dL, use of medication for
diabetes mellitus, or a clinical diagnosis of diabetes mellitus
(adjudicated as conﬁrmed or probable). Body mass index
(BMI) was computed using visit-speciﬁc weight and baseline
height. Ten-year risk scores were calculated at baseline and
updated during follow-up for the following18–21: (1) Framing-
ham Risk Score for a CVD or CHD event; (2) D:A:D (Data
Collection on Adverse Events of Anti-HIV Drugs) risk score for
a CVD or CHD event; and (3) the pooled cohort risk
assessment for an atherosclerotic CVD event.
Statistical Methods
The mean changes from baseline between the immediate and
deferred groups for continuous measures were compared
using longitudinal mixed models with random intercepts,
including treatment group, visit, and baseline value in the
model. The differences between groups for the prevalence of
binary measures were compared using generalized estimating
equations (binomial regression) with treatment group, visit,
and baseline prevalence in the model. Histograms showed
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that total cholesterol, LDL-C, HDL-C, and BP were approxi-
mately normally distributed and were analyzed untrans-
formed. The proportional hazards assumption was tested
using log-time as a covariate in the model. Comparisons
within subgroups deﬁned by prespeciﬁed ART drug or class
(efavirenz [EFV], PI, or INSTI) are reported. EFV-based ART was
included as a subgroup in analyses by ART class, given that
EFV represented 95% of the NNRTI use in the START trial.
Incidence for binary risk factors was determined in partici-
pants without that condition at baseline using a single factor
for treatment in Cox regression models. To directly compare
treated versus untreated HIV infection we repeated the
analyses by excluding immediate group participants who
never started ART (n=39) and censoring the deferred group at
the time of ART initiation. Analyses were performed using SAS
software version 9.3 (SAS Institute Inc) and R software
version 3.2.3 (R Foundation for Statistical Computing).
Results
Participant Characteristics
A total of 4685 HIV-positive individuals from 215 sites in 35
countries were enrolled into the START trial. The median age
of participants was 36 years and 27% were female
(Table 1).22 Self-reported race/ethnicity reﬂected global
enrollment from the United States (11%), South America
and Mexico (25%), Europe, Israel and Australia (35%), Africa
(21%), and Asia (8%). The CD4+ cell count at entry was 651
cells/mm3, and the median time since HIV diagnosis was
1 year. Mean (SD) and median [interquartile range] follow-up
time was 3.0 (1.2) and 2.8 [2.1–3.9] years, respectively, with
no difference in follow-up time between the immediate and
deferred groups. Baseline characteristics did not differ
between groups (Table 1). In addition to a high smoking
prevalence, START trial participants were at low risk for CVD
based on the median values for BMI, BP, cholesterol, and
CVD/CHD risk scores.
The percentage of participants taking ART during follow-
up is presented in Figure 1; 98% of the immediate group and
48% of the deferred group initiated ART, with a median time
to initiation of 36 months in the deferred group. The
percentage of follow-up time spent taking ART was 94%
and 28% for the immediate and deferred groups, respec-
tively. The frequency of speciﬁc antiretrovirals in the initial
ART regimen reﬂects contemporary clinical practice
(Table S1). Among the 2287 immediate group participants
who initiated therapy, ART included tenofovir disoproxil
fumarate in 89%, an NNRTI in 77% (73% EFV), a ritonavir-
boosted PI in 19% (10% atazanavir and 7% darunavir), and an
INSTI in 5% (4% raltegravir); corresponding values for the
1134 deferred group participants who initiated therapy
included tenofovir disoproxil fumarate in 89%, an NNRTI in
64% (51% EFV), a PI in 22% (11% darunavir), and an INSTI in
14% (8% raltegravir).
Changes in Serum Cholesterol Levels and Lipid-
Lowering Therapy
Mean changes in lipid levels (Figure 2) and the incidence of
dyslipidemia (Figure 3) are presented for each group.
Compared with the ART deferral group, the immediate ART
group had 11 mg/dL higher total cholesterol (95% CI, 10–
13), 6 mg/dL higher LDL-C (95% CI, 4–7), and 5 mg/dL
higher HDL-C (95% CI, 4–5) levels. The rise in total
cholesterol and LDL-C in the immediate group was associ-
ated with a 1.2% greater use of lipid-lowering therapy (95%
CI, 0.2–2.2) and a higher incidence rate of dyslipidemia
(hazard ratio, 1.7; 95% CI, 1.4–2.02). Among the 346
participants taking lipid-lowering therapy at entry or during
follow-up, 68% were taking a statin. Increases in HDL-C
levels resulted in a marginally lower total cholesterol to HDL-
C ratio in the immediate versus the deferred group (0.1;
95% CI, 0.2 to 0.1). When HDL <40 mg/dL was included
in the criteria for dyslipidemia, 49% (2283) of participants
had dyslipidemia at study entry. When including low HDL in
the deﬁnition, the incidence rate for dyslipidemia was lower
in the immediate ART group compared with the deferred ART
group (hazard ratio, 0.7; 95% CI, 0.6–0.8) (Figure 3).
Immediate ART also resulted in higher triglyceride (8 mg/
dL; 95% CI, 3–12) and non–HDL-C (7 mg/dL; 95% CI, 5–8)
levels than deferred ART. Participants were fasting for 91%
of blood draw visits and the ﬁndings were similar when
analyses were restricted to fasting specimens. In analyses of
treated versus untreated HIV infection, the treatment
differences in lipid changes from baseline were of higher
magnitude but similar.
Table 2 presents analyses of subgroups deﬁned by
prespeciﬁed ART, with comparisons for EFV-, PI-, and INSTI-
based ART. These data represent the effect of starting a
speciﬁc antiretroviral when compared with a group random-
ized to defer ART but who intended to start the same
antiretroviral medication or class. Time spent during follow-up
taking the prespeciﬁed ART varied between 75% and 80% for
the immediate group and 15% and 20% for the deferred group.
There was a signiﬁcant interaction between the prespeciﬁed
ART regimen and the treatment difference for several
cholesterol measures. Speciﬁcally, participants who prespec-
iﬁed EFV use had a greater difference in both total cholesterol
and HDL-C level between the immediate and deferred groups,
when compared with those who prespeciﬁed PI use. Similarly,
when compared with those who prespeciﬁed an INSTI, the
EFV subgroup had greater differences in total cholesterol,
LDL-C, and HDL-C levels between the immediate and deferred
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groups. Notably, there was no difference in any lipid
parameters between immediate and deferred ART among
the subgroup that prespeciﬁed INSTI use. In analyses of
treated versus untreated HIV infection, the magnitude of the
treatment differences in lipid changes from baseline was
higher for EFV- and PI-based ART.
Changes in BP
When compared with patients who underwent ART deferral,
those who took immediate ART demonstrated no difference
in systolic BP, a lower diastolic BP that was not signiﬁcant
(Figure 2), and a lower prevalence of BP-lowering therapy
(2.2%; 95% CI, 3.6 to 0.93). At entry, 19% of
participants had hypertension (per our deﬁnition), and when
new-onset hypertension rates were compared between the
immediate and deferred groups, the hazard ratio for reduced
incidence of hypertension did not reach signiﬁcance (0.87;
95% CI, 0.74–1.02; [P=0.10]) (Figure 3). After analyses of
treated versus untreated HIV infection, there remained no
difference in use of BP-lowering therapy or incident hyper-
tension between the groups, whereas diastolic BP was
signiﬁcantly lower in the immediate ART group (0.4; 95%
CI, 0.1 to 0.7 [P=0.02]).
Changes in Metabolic Parameters
Patients in the immediate group had a higher mean glucose
level of 2 mg/dL (95% CI, 1–3) than patients in the deferred
group (Figure S1), but there was no difference in the incidence
Table 1. Baseline Characteristics of Patients in the START
Trial (n=4685)
Median [IQR] or % (No.)
Demographics
Age, y 36 [29–44]
Female sex 26.8 (1257)
Race
Asian 8.3 (388)
Black 30.1 (1410)
Latino/Hispanic 13.6 (638)
White 44.5 (2086)
Other 3.5 (163)
HIV history and laboratory
Time known to be HIV positive, y 1.0 [0.4–3.1]
CD4, cells/mm3* 651 [584–765]
Nadir CD4, cells/mm3† 553 [488–654]
HIV RNA, copies/mL 12 759 [3019–43 391]
Clinical measures
BMI, kg/m2 24.6 [22.1–27.9]
Systolic BP, mm Hg 120 [111–130]
Diastolic BP, mm Hg 76 [70–83]
Risk factors
Current smoker 31.9 (1496)
Diabetes mellitus 3.3 (156)
Prior CVD diagnosis‡ 0.8 (36)
Hypertension 19.2 (898)
BP-lowering drugs 8.1 (281)
Dyslipidemia 8.2 (386)
Lipid-lowering drugs 3.5 (163)
Glucose and lipids
Glucose, mg/dL 85 [79–92]
Total cholesterol, mg/dL 168 [144–195]
LDL-C, mg/dL 102 [82–124]
HDL-C, mg/dL 41 [35–50]
Triglycerides, mg/dL 97 [71–142]
Total cholesterol to HDL-C ratio 4.0 [3.2–5.0]
Non–HDL-C, mg/dL 124 [102–150]
10-year predicted risk scores
CVD FRS, %§ 2.3 [0.7–6.5]
CHD FRS, %§ 1.9 [0.5–5.0]
CVD D:A:D, %k 1.8 [0.9–3.5]
CHD D:A:D, %k 1.4 [0.7–2.9]
Pooled cohort ASCVD, %¶ 2.2 [1.0–4.4]
Lifetime ASCVD risk score, %# 31.2 [15.6–39.6]
Continued
Table 1. Continued
Median [IQR] or % (No.)
Prespecified ART regimen
EFV 75.1 (3516)
PI 17.4 (815)
INSTI 3.9 (183)
Non-EFV NNRTI 3.7 (171)
ART indicates antiretroviral therapy; BMI, body mass index; BP, blood pressure; CHD,
coronary heart disease; CVD, cardiovascular disease; EFV, efavirenz; HDL-C, high-density
lipoprotein cholesterol; INSTI, integrase strand transfer inhibitor; IQR, interquartile range;
LDL-C, low-density lipoprotein cholesterol; NNRTI, non-nucleoside reverse transcriptase
inhibitor; PI, protease inhibitor; START, Strategic Timing of Antiretroviral Treatment.
*Average of 2 screening values.
†Documented in participant record.
‡Diagnosis of any of the following prior to randomization: myocardial infarction, stroke,
coronary heart disease requiring drug treatment, coronary revascularization, congestive
heart failure, or peripheral arterial disease.
§Framingham Risk Score (FRS) equations in Anderson et al.18
kData Collection on Adverse Events of Anti-HIV Drugs (D:A:D) score equations in Friis-
Møller et al.19
¶Atherosclerotic cardiovascular disease (ASCVD) risk equation in Goff et al.20
#Lifetime ASCVD risk score in Berry et al.22
DOI: 10.1161/JAHA.116.004987 Journal of the American Heart Association 4
Cardiovascular Disease Risk Factors in the START Trial Baker et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on Septem
ber 15, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
of type 2 diabetes mellitus (Figure 3). In contrast, BMI was
signiﬁcantly lower among patients in the immediate versus
deferred groups (0.2 kg/m2; 95% CI,0.3 to0.1), although
the magnitude of this effect is of unclear clinical signiﬁcance
(Figure S1). The treatment effect on BMI appeared greatest
early after randomization (P<0.001 for interaction of treatment
group by follow-up time). When comparing subgroups deﬁned
by prespeciﬁed ART regimen, BMI showed a signiﬁcantly
greater decline (with immediate versus deferred ART) among
patients in the EFV (0.3 kg/m2; 95% CI,0.4 to0.2) versus
PI (0.1 kg/m2; 95% CI,0.2 to 0.1) subgroups. Finally, there
was no evidence of an interaction between prespeciﬁed ART
regimen and a treatment effect for serum glucose or incident
diabetes mellitus.
Differences in Risk Factor Proﬁle and Predicted
Risk Scores
We studied the effect of immediate ART on CVD and CHD
predicted risk scores. Smoking contributed the most to
predicted risk, but rates did not differ between treatment
groups during follow-up (Figure S1). The mean difference
between groups was not signiﬁcant for the atherosclerotic
CVD pooled cohort 10-year risk score (0.1; 95% CI, 0.2 to
0.1), the Framingham Risk Score 10-year CVD (0.1; 95%
CI, 0.3 to 0.0), or the Framingham Risk Score 10-year
CHD (0.1; 95% CI 0.3 to 0.0), but was slightly higher in
the immediate group for the D:A:D 10-year CVD (0.2; 95% CI,
0.1–0.3) and CHD (0.1; 95% CI, 0.1–0.2) estimates. Differ-
ences in the D:A:D scores were caused primarily by the fact
that this score considers exposure to certain antiretrovirals
(eg, abacavir, lopinavir); there were no differences when
censoring participants after initiation of these antiretrovirals.
After analyses of patients with treated versus untreated HIV
infection, the treatment differences in the Framingham Risk
Score estimates were of a similar low magnitude but reached
statistical signiﬁcance.
Discussion
The START trial is the ﬁrst randomized clinical investigation to
study the impact of immediate ART initiation, when compared
with deferral, on CVD risk factors among a large global HIV-
positive cohort with high CD4+ cell counts. It is in this context
that understanding and mitigating risk for CVD becomes a
high priority in clinical practice. When compared with ART
deferral, ART initiation increased total cholesterol and LDL-C
levels and use of lipid-lowering therapy, but also increased
HDL-C level and resulted in a decline in total cholesterol to
HDL-C ratio. Changes in CVD or CHD prediction scores
with immediate versus deferred ART were minimal or
nonsigniﬁcant.
A well-described consequence of untreated HIV infection is
a decline in most serum lipids levels (the primary exception
being an elevation in triglycerides), with ART initiation then
leading to a compensatory increase in total cholesterol and
LDL-C levels to a degree that often varies by regimen.15,23,24
We present novel randomized data quantifying the absolute
effect of ART initiation on serum lipids, when compared with
initially untreated HIV disease. Increases in total cholesterol
were greatest among the subgroups that prespeciﬁed EFV.
Prior studies have lacked a comparison group of untreated
persons, but have reported greater within-participant
increases in total cholesterol (mean 19 and 55 mg/dL) and
LDL-C (mean 4 and 23 mg/dL) levels 1 year after starting
NNRTI- (eg, EFV) or PI-based ART, when compared with the
changes reported in the START trial.15,25,26 It is unclear
whether the greater increases in LDL-C level with EFV-based
ART reﬂects greater CVD risk, given that increases in HDL-C
level were also greater with EFV and that epidemiologic data
demonstrate that exposure to certain PIs, but not to NNRTIs
(eg, EFV), are associated with greater risk for myocardial
infarction.10,27
Data from comparative antiretroviral trials have shown
the greatest rises in HDL-C level after starting EFV (73% in
the START trial) or tenofovir (89% in the START trial), with
the effect from INSTIs (5% in the START trial) being
0
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Figure 1. Antiretroviral therapy (ART) use by treatment
group in the START (Strategic Timing of Antiretroviral
Treatment) trial (n=4685). Shown is the percentage of
participants taking ART by follow-up month in the immedi-
ate and deferred ART groups. Datawere previously reported
but the results shown here are truncated at month 48.16
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Figure 2. Cardiovascular risk factor changes by treatment group. Shown in the ﬁrst 3 rows are the
unadjustedmean changes frombaseline at annual visits for participants in the immediate (I) and deferred (D)
antiretroviral therapy (ART) groups for the following measures: total cholesterol (A), low-density lipoprotein
cholesterol (LDL-C; B), high-density lipoprotein cholesterol (HDL-C; C), total cholesterol to HDL-C ratio (D),
systolic blood pressure (BP; E), and diastolic BP (F). Presented within (A through F) are the estimated mean
differences (with 95% CIs and P values) during follow-up between the 2 groups (I minus D), adjusting for the
baseline value and visit from longitudinal mixed models. Shown in the last row is the unadjusted prevalence
(percentage) at baseline and follow-up annual visits for participants in both ART groups for use of BP-lowering
drugs (G) and lipid-lowering drugs (H). Presented within (G and H) are the overall estimated differences in
prevalence during follow-up (with 95% CIs and P values) between the 2 groups (I minus D), adjusting for the
baseline prevalence and visit from generalized estimating equations. Figures are truncated at month 48.
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mixed.25,26,28–32 Our ﬁndings support that ART initiation with
EFV-based ART led to the greatest increases in HDL-C level.
Furthermore, the degree of HDL-C level increase attributable
to initiating EFV-based ART was large enough to result in a
concurrent decline in the ratio of total cholesterol to HDL-C,
which was not observed for PI- or INSTI-based ART. The
differential effect on HDL-C level by ART regimen and lack of
signiﬁcant INSTI effects on any blood lipids suggests that
cholesterol changes may, in part, be mediated via effects
other than those related to HIV viral suppression.
Multiple factors contribute to dyslipidemia among ART-
treated HIV-positive patients, including altered hepatic syn-
thesis, inﬂammation, oxidative stress, direct drug toxicity (eg,
PI binding of the LDL-C receptor protein), and possibly genetic
factors.23,33–35 The modest degree of ART-associated
increases in total cholesterol and LDL-C levels described in
the START trial was surprising, although, as noted, may be
caused by the fact that previous estimates cannot isolate the
net effect of ART versus no ART. One important caveat to the
increase in dyslipidemia with immediate ART in the START trial
was that if low HDL level was included as criteria, then
dyslipidemia was less with immediate ART. Another important
difference between ﬁndings from the START trial and most
prior ART trials is the health of the study population, raising
the question of whether ART-related effects on serum lipids
may be decreased when initiating treatment earlier in HIV
disease. Still, the effect of ART treatment on blood lipid levels
in the START trial emphasizes that cholesterol should remain
a key target for CVD risk factor modiﬁcation within this
population.
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Figure 3. Cumulative incidence of comorbid conditions by treatment group. Shown are Kaplan–Meier
estimates of the cumulative incidence of participants with dyslipidemia, excluding high-density lipoprotein
(HDL) in the deﬁnition (A), dyslipidemia, including HDL <40 mg/dL in the deﬁnition* (B), hypertension† (C),
and diabetes mellitus (D) during follow-up for participants in the immediate (I) and deferred (D) antiretroviral
therapy (ART) groups. Presented within the ﬁgures are the estimated hazard ratios (HRs) for the immediate
(I) vs deferred (D) groups (with 95% CIs and P values) from Cox proportional hazards regression models.
Figures are truncated at month 48. The cumulative incidence plots have jumps annually because
measurements were obtained only at annual visits. *A total of 2203 (49%) START (Strategic Timing of
Antiretroviral Treatment) trial participants had dyslipidemia at baseline when including the criteria of HDL
<40 mg/dL. The incidence computation during follow-up for this deﬁnition is limited to the 2402
participants without baseline dyslipidemia. †For the incidence computation, an individual was deﬁned as
being hypertensive at the ﬁrst visit when systolic blood pressure (BP) was ≥140 mm Hg, diastolic BP was
≥90 mm Hg, or BP medication use was reported. In some individuals classiﬁed as hypertensive based on
BP alone, the BP may be lower at subsequent visits. This deﬁnition leads to a higher incidence.
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Although immediate ART initiation did not lead to signiﬁcant
changes in BP or incident hypertension, the use of BP-lowering
therapy and the prevalence of hypertension were less with
immediate ART. Reasons for this discrepancy are unclear, but
incident hypertension does not reﬂect inﬂuences on the use of
BP-lowering therapy among patients with known hypertension
at entry. Associations between inﬂammatory cytokines and
vascular stiffness provide some biologic pretense for why
suppressing HIV replication may reduce the need for BP
therapy.36–39 However, if a true ART-treatment effect on
absolute BP was present but not detected in this study (eg,
type 2 error), it is unlikely to be clinically signiﬁcant.
ART is well known to be associated with body composition
changes, although contemporary ART regimens are less toxic
than early-era antiretrovirals.40–42 In the START trial, imme-
diate ART initiation led to a clinically insigniﬁcant increase in
serum glucose (ie, with no change in incidence of diabetes
mellitus), but was also associated with a marginally lower BMI.
The BMI ﬁndings are counter to prior observations of ART
increases in abdominal fat, but, importantly, BMI assessments
do not delineate between changes in visceral and subcuta-
neous fat.41,43 In addition, the relative immune preservation in
the START trial may be important in that toxicity from a given
antiretroviral medication may be more pronounced among
patients with more severe immune depletion. This hypothesis
was suggested by notable ﬁndings from HOPS (the HIV
Outpatient Study), in which starting ART at higher (versus
lower) CD4+ cell counts reduced the incidence of peripheral
neuropathy, even when using antiretrovirals well known to
cause neuropathy.44
Ultimately, the net effect of early ART initiation on
traditional risk factors appeared to have a clinically insignif-
icant effect on CVD and CHD risk algorithms. While 10-year
CVD/CHD predicted risk remained low in absolute terms, the
estimated lifetime atherosclerotic CVD risk at study entry
among this younger population was still >30%,22 reinforcing
that traditional risk factor management remains an important
strategy to mitigate the cumulative effects of HIV, ART, and
advancing age over time. However, it does remain unclear
how well the atherosclerotic CVD lifetime risk estimation
reﬂects true clinical risk in this context as it has not been
validated among HIV-positive persons.
Study Limitations
These analyses have several limitations. We did not directly
assess or characterize other potentially important CVD risk
mechanisms (eg, HIV-related systemic inﬂammation) or
potential mechanisms of ART toxicity. There was potential
for confounding in terms of baseline lipid levels inﬂuencing
the choice of ART regimen; however, we did not see evidence
for this, as the prevalence of prespeciﬁed PI (17%) was the
same for persons with and without hyperlipidemia at baseline.
Also, analyses focused on the INSTI subgroup were limited by
small numbers. Finally, we are not able to characterize
whether the ART-related changes in CVD risk factors will
translate to differences in clinical event risk caused by the
limited number of events in the START trial, although ﬁndings
to date have not detected a signiﬁcant effect of immediate
versus deferred ART on risk for CVD events (HR, 0.84; 95% CI,
0.39–1.81).16
Conclusions
These data, among a diverse global population of HIV-positive
persons with high CD4 cell counts, suggest that immediate
ART initiation has both positive and negative inﬂuences on
CVD risk factors. Ultimately, long-term follow-up in the START
trial is needed to determine the net effect of ART treatment
initiation for CVD event risk among HIV-positive individuals
with preserved immunity.
Table 2. Overall Treatment Difference (I–D) in Metabolic Parameters by Subgroups Deﬁned by Prespeciﬁed ART Regimen at
Baseline
Measure
Prespeciﬁed ART
Interaction
P Value†
EFV (n=3516) PI (n=815) INSTI (n=183)
I–D
Mean Difference* (95% CI)
I–D
Mean Difference* (95% CI)
I–D
Mean Difference* (95% CI)
Total cholesterol, mg/dL 13.2 (11.5–14.9) 8.7 (5.2–12.1) 2.4 (10.1 to 5.3) <0.001
LDL-C, mg/dL 6.5 (5.0–7.9) 3.7 (0.7–6.7) 1.1 (7.8 to 5.7) 0.036
HDL-C, mg/dL 5.8 (5.2–6.4) 2.2 (0.9–3.5) 0.4 (2.5 to 3.4) <0.001
Total cholesterol to HDL-C ratio 0.2 (0.2 to 0.1) 0.0 (0.2 to 0.1) 0.2 (0.5 to 0.2) 0.13
EFV indicates efavirenz; HDL-C, high-density lipoprotein cholesterol; INSTI, integrase strand transfer inhibitor; LDL-C, low-density lipoprotein cholesterol; PI, protease inhibitor.
*Mean differences (immediate [I] minus deferred [D]) during all follow-up using longitudinal mixed models adjusting for baseline level and visit.
†2 df P value for interaction between treatment group and 3 prespeciﬁed antiretroviral therapy (ART) regimens comparing the I–D treatment difference among subgroups.
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Table S1. Distribution (number and percent) of specific ART used for the first regimen 
and total follow-up time spent taking a specific ART (Person Years, percent of follow-up). 
 
 
  Immediate Deferred 
  
First Regimen 
N(%)* 
Cumulative 
Follow-up Time 
on Drug  
PY(% time)† 
First Regimen 
N(%)* 
Cumulative 
Follow-up Time 
on Drug  
PY(% time)† 
No. of participants 2326 2359 
 
        
Any NRTI 2285 (98.2) 6582 (93.9) 1131 (47.9) 1954 (27.7) 
Abacavir 72 (3.1) 344 (4.9) 70 (3.0) 154 (2.2) 
Emtricitabine 2025 (87.1) 5794 (82.7) 1001 (42.4) 1724 (24.4) 
Tenofovir 2026 (87.1) 5821 (83.1) 1012 (42.9) 1735 (24.6) 
Lamivudine 260 (11.2) 779 (11.1) 129 (5.5) 225 (3.2) 
Zidovudine 188 (8.1) 411 (5.9) 47 (2.0) 63 (0.9) 
Other 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 
        
Any NNRTI 1759 (75.6) 4524 (64.6) 722 (30.6) 1122 (15.9) 
efavirenz 1661 (71.4) 4097 (58.5) 573 (24.3) 855 (12.1) 
rilpivirine 97 (4.2) 360 (5.1) 141 (6.0) 237 (3.4) 
other 1 (0.0) 68 (1.0) 8 (0.7) 31 (0.4) 
 
        
Any PI 424 (18.2) 1653 (23.6) 252 (10.7) 553 (7.8) 
atazanavir 230 (9.9) 887 (12.7) 99 (4.2) 220 (3.1) 
darunavir 165 (7.1) 611 (8.7) 125 (5.3) 290 (4.1) 
fosamprenavir 11 (0.5) 33 (0.5) 6 (0.3) 13 (0.2) 
lopinavir 18 (0.8) 121 (1.7) 21 (0.9) 30 (0.4) 
ritonavir 422 (18.1) 1630 (23.3) 250 (10.6) 547 (7.8) 
other 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 
        
Any INSTI 103 (4.4) 448 (6.4) 157 (6.7) 288 (4.1) 
dolutegravir 1 (0.0) 10 (0.1) 19 (0.8) 21 (0.3) 
elvitegravir 1 (0.0) 25 (0.4) 49 (2.1) 63 (0.9) 
raltegravir 101 (4.3) 413 (5.9) 89 (3.8) 205 (2.9) 
other 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 
        
Other ART‡ 1 (0.0) 2 (0.0) 0 (0.0) 0 (0.0) 
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Not on any ART 39 (1.7) 400 (5.7) 1225 (51.9) 5094 (72.2) 
 
        
         
N – number; PY – Person years; ART – Antiretroviral therapy; NRTI – nucleoside reverse transcriptase inhibitor; NNRTI – non-
nucleoside reverse transcriptase inhibitor; PI – protease inhibitor; INSTI – integrase strand transfer inhibitor 
* Denominator is all participants in the randomization group. 
† Person years includes switches and accounts for stops and therefore includes time spent on drug for participant who did not 
initiate ART with the given  
  drug. Denominator is over all follow-up time accumulated within the randomization group.   
‡ 1 participant started a blinded study and the type of ART taken is unknown.   
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Figure S1. Changes in the Prevalence of Selected CVD Risk Factors by Treatment Group  
 
 
 
Shown in panels A-C is the unadjusted prevalence (%) at baseline and follow-up annual visits 
for participants in the immediate (I, solid line) and deferred (D, dashed line) ART groups for 
CVD (cardiovascular disease) risk factor, including hypertension (panel A), dyslipidemia (panel 
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B), and current smoking (panel C). Presented within panels A-C are overall estimated 
differences in prevalence (with 95% confidence interval and p-value) over follow-up between the 
two groups (immediate minus deferred), adjusting for the baseline prevalence and visit from 
generalized estimating equations.  Shown in panels D-E are the unadjusted mean changes from 
baseline at annual visits for participants in both ART groups for the following measures: body 
mass index (BMI, panel D) and glucose (panel E). Presented within panels D-E is the estimated 
mean difference (with 95% confidence interval and p-value) over follow-up between the two 
groups (immediate minus deferred), adjusting for the baseline value and visit from longitudinal 
mixed models.  Figures are truncated at Month 48.   
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Appendix: The INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study 
Group 
 
In addition to writing group, the following committee members contributed to the conduct of the START 
trial:  
 
Community Advisory Board: C. Rappoport (INSIGHT community liaison), P.D. Aagaard, S. Collins, 
G.M. Corbelli, N. Geffen, C. Kittitrakul, T. Maynard, M. Meulbroek, D. Munroe, M.S. Nsubuga, D. 
Peavey, S. Schwarze, M. Valdez.  
 
Substudy Chairs: J.V. Baker, D. Duprez (arterial elasticity); A. Carr, J. Hoy (bone mineral density); M. 
Dolan, A. Telenti (genomics); C. Grady (informed consent); G. Matthews, J. Rockstroh (liver fibrosis 
progression); W.H. Belloso, J.M. Kagan (monitoring); E. Wright, B. Brew, R.W. Price, K. Robertson, L. 
Cysique (neurology); K.M. Kunisaki, J.E. Connett, D.E. Niewoehner (pulmonary). Endpoint Review 
Committee: A. Lifson (chair), W.H. Belloso, R.T. Davey Jr., D. Duprez, J.M. Gatell, J. Hoy, C. Pedersen, 
R.W. Price, R. Prineas, J. Worley.  
 
Central Drug Repository and Drug Distribution: K. Brekke, S. Meger, B. Baugh, J. Eckstrand, C. 
Gallagher, J. Myers, J. Rooney, J. Van Wyk.  
 
Network Laboratory Group: J. Baxter, C. Carey, A. DuChene, E.B. Finley, M. George, J. Grarup, M. 
Hoover, R. Pedersen, C. Russell, B. Standridge.  
 
Specimen Repositories: E. Flowers, M. Hoover, K. Smith (Advanced BioMedical Laboratories, LLC, 
Cinnaminson, NJ, United States); M. McGrath, S. Silver (AIDS and Cancer Specimen Resource, 
University of California, San Francisco, San Francisco, CA, United States).  
 
Wake Forest ECG Reading Center, Winston-Salem, NC, United States: E.Z. Soliman, M. Barr, C. 
Campbell, S. Hensley, J. Hu, L. Keasler, Y. Li, T. Taylor, Z.M. Zhang.  
 
Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States: B. 
AlstonSmith, E. DeCarlo, K. Klingman, M. Proschan.  
 
Data and Safety Monitoring Board: S. Bangdiwala (chair), R. Chaisson, A.R. Fleischman, C. Hill, J. 
Hilton, O.H.M. Leite, V.I. Mathan, B. Pick, C. Seas, P. Suwangool, G. Thimothe, F. Venter, I. Weller, P. 
Yeni.  
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 Minnesota Coordinating Center, University of Minnesota, Minneapolis, MN, United States: J.D. Neaton, 
K. Brekke, G. Collins, E.T. Denning, A. DuChene, N.W. Engen, M. George, B. Grund, M. Harrison, K.H. 
Hullsiek, L.H. Klemme, E. Krum, G. Larson, S. Meger, R. Nelson, J. Neuhaus Nordwall, K. Quan, S.F. 
Quan, T. Schultz, S. Sharma, G. Thompson.  
 
International Coordinating Centers: Copenhagen HIV Programme, Rigshospitalet, University of 
Copenhagen, Denmark: J.D. Lundgren, B. Aagaard, A.H.D. Borges, M. Eid, J. Grarup, P. Jansson, Z. 
Joensen, B. Nielsen, M. Page 3 Pearson, R. Pedersen, A.N. Phillips; The Kirby Institute, University of 
New South Wales, Sydney, Australia: S. Emery, N. Berthon-Jones, C. Carey, L. Cassar, M. Clewett, D. 
Courtney-Rodgers, P. Findlay, S. Hough, S. Jacoby, J. Levitt, S.L. Pett, R. Robson, V. Shahamat, A. 
Shambrook; Medical Research Council Clinical Trials Unit at UCL, London, United Kingdom: A.G. 
Babiker, B. Angus, A. Arenas-Pinto, R. Bennett, N. Braimah, E. Dennis, N. Doyle, M. Gabriel, F. 
Hudson, B. Jackson, A. Palfreeman, N. Paton, C. Purvis, C. Russell; Veterans Affairs Medical Center, 
Washington, DC, United States: F. Gordin, D. Conwell, H. Elvis, E.B. Finley, V. Kan, L. Lynch, J. 
Royal, A. Sánchez, B. Standridge, D. Thomas, M. Turner, M.J. Vjecha.  
 
The following investigators participated in the START study, listed by country (country lead, numbers of 
participants enrolled) and clinical site:  
 
Argentina (M.H. Losso, n=216): CAICI (Instituto Centralizado de Assistencia e Investigación Clínica 
Integral), Rosario Santa Fe: S. Lupo, L. Marconi, D. Aguila; FUNCEI, Buenos Aires: G. Lopardo, E. 
Bissio, D. Fridman; Fundación IDEAA, Buenos Aires: H. Mingrone, E. Loiza, V. Mingrone; Hospital 
General de Agudos JM Ramos Mejia, Buenos Aires: M. Losso, J.M. Bruguera, P. Burgoa; Hospital 
Interzonal General de Agudos Dr. Diego Paroissien, Buenos Aires: E. Warley, S. Tavella; Hospital 
Italiano de Buenos Aires, Buenos Aires: W. Belloso, M. Sanchez; Hospital Nacional Profesor Alejandro 
Posadas, Buenos Aires: H. Laplumé, L. Daciuk; Hospital Rawson, Cordoba: D. David, A. Crinejo; 
Argentinean SCC, Fundación IBIS, Buenos Aires: G. Rodriguez-Loria, L. Doldan, A. Moricz, I. Otegui, 
I. Lanusse.  
 
Australia (J. Hoy, n=109): Burwood Road General Practice, Burwood, VIC: N. Doong, S. Hewitt; Centre 
Clinic, St Kilda, VIC: B.K. Tee; East Sydney Doctors, Darlinghurst, NSW: D. Baker, E. Odgers; 
Holdsworth House Medical Practice, Darlinghurst, NSW: S. Agrawal, M. Bloch; Melbourne Sexual 
Health Centre, Carlton, VIC: T.R.H. Read, S.J. Kent; Prahran Market Clinic, Prahran, VIC: H. Lau, N. 
Roth; Royal Adelaide Hospital, Adelaide, SA: L. Daly, D. Shaw; Royal Perth Hospital, Perth, WA: M. 
French, J. Robinson; Sexual Health & HIV Service - Clinic 2, Brisbane, QLD: M. Kelly, D. Rowling; St 
Vincent's Hospital, Fitzroy, VIC: D.A. Cooper, A. J. Kelleher; Taylor Square Private Clinic, Surry Hills, 
NSW: C. Pell, S. Dinning; The Alfred Hospital, Melbourne, VIC: J. Hoy, J. Costa; Westmead Hospital, 
Westmead, NSW: D.E. Dwyer, P. King.  
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Austria (A. Rieger, n=7): Otto-Wagner-Spital SMZ /Baumgartner Hoehe, Vienna: N. Vetter; B. Schmied; 
University Vienna General Hospital, Vienna: A. Rieger, V.R. Touzeau.  
 
Belgium (S. de Witt, n=102): Centre Hospitalier Universitaire St. Pierre (C.H.U. St. Pierre), Brussels: S. 
de Witt, N. Clumeck, K. Kabeya; Institute of Tropical Medicine, Antwerp: E. Cleve, E. Florence, L. van 
Petersen; Universitair Ziekenhuis Gasthuisberg, Leuven: H. Ceunen, E.H. van Wijngaerden; Universitaire 
Ziekenhuizen Gent, Gent: T. James, L. Vandekerckhove.  
 
Brazil (L.C. Pereira Jr., M. Schechter, n=619): Ambulatório de Imunodeficiências (LIM-56), Sao Paulo, 
SP: J. Casseb, E. Constantinov, M.A. Monteiro; Center for ID at UFES, Vitoria, ES: L.N. Passos, T. 
Reuter; Centro de Referência e Treinamento DST/AIDS, Sao Paulo, SP: S.T. Leme, J.V.R. Madruga, R.S. 
Nogueira; Hospital Page 4 Escola Sao Francisco de Assis, Rio de Janeiro, RJ: M. Barbosa Souza, C. 
Beppu Yoshida, M. Dias Costa; Instituto de Infectologia Emilio Ribas, Sao Paulo, SP: R. Castro, R.Cruz, 
S. Ito, T.N. Lobato Souza; Instituto FIOCRUZ, Rio de Janeiro, RJ: B. Grinsztejn, V.G. Veloso, S. 
Wagner Cardoso; SEI Serviços Especializados em Infectología LTDA, Salvador, Bahia: F. Bahia, C. 
Brites, J. Correia.  
 
Chile (M.J. Wolff, n=76): Fundación Arriarán, Santiago: M. Wolff, R. Northland, C. Cortés.  
 
Czech Republic (D. Sedlacek, n=13): Faculty Hospital Na Bulovce, Prague: D. Jilich; University Hospital 
Plzen, Plzen: D. Sedlacek.  
 
Denmark (J. Gerstoft, n=33): Hvidovre University Hospital, Hvidovre: P. Collins, L. Mathiesen; Odense 
University Hospital, Odense: L. Hergens, C. Pedersen; Rigshospitalet, Copenhagen: J. Gerstoft, L.P. 
Jensen; Århus Universitetshospital, Skejby, Århus: I.R. Lofthiem, L. Østergaard.  
 
Estonia (K. Zilmer, n=8): West Tallinn Central Hospital Infectious Diseases, Tallinn: K. Zilmer.  
 
Finland (M. Ristola, n=23): Helsinki University Central Hospital, Helsinki: M. Ristola, O. Debnam.  
 
France (B. Hoen, n=111): CHU Côte de Nacre – Caen, Caen: R. Verdon, S. Dargere; CHU de Besançon - 
Hôpital Jean-Minjoz, Besancon: B. Hoen, C. Chirouze; Groupe Hospitalier Pitié-Salpêtrière, Paris: C. 
Katlama, M-A. Valantin; Hôpital Antoine Béclère, Clamart: F. Boue, I. Kansau; Hôpital de Bicêtre, Le 
Kremlin-Bicetre: C. Goujard, C. Chakvetadze; Hôpital Européen Georges Pompidou, Paris: L. Weiss, M 
Karmochkine; Hôpital Foch, Suresnes: D. Zucman, C. Majerholc; Hôpital Gustava Dron, Tourcoing: 
O.Robineau, R. Biekre; Hôpital Henri Mondor, Creteil: Y. Levy, J.D. Lelievre; Hôpital Hôtel Dieu, Paris: 
J.P. Viard, J Ghosn; Hôpital Saint-Antoine, Paris: J. Pacanowski, B. Lefebvre; Hôpital Saint-Louis, Paris: 
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J.-M. Molina, L. Niedbalski, M. Previlon; French SCC, ANRS-Inserm SC10, Paris: J.P. Aboulker, C. 
Capitant, B. Lebas, N. Leturque, L. Meyer, E. Netzer.  
 
Germany (G. Fätkenheuer, n=312): EPIMED, Berlin: K. Arastéh, T. Meier; Gemeinschaftspraxis Jessen-
JessenStein, Berlin: C. Zedlack, H. Jessen; ICH Study Center, Hamburg: S. Heesch, C. Hoffmann; Ifi - 
Studien und Projekte GmbH, Hamburg: A. Plettenberg, A. Stoehr; Johann Wolfgang Goethe - University 
Hospital, Frankfurt: G. Sarrach, C. Stephan; Klinik I für Innere Medizin der Universität zu Köln, 
Cologne: G. Fätkenheuer, E. Thomas; Klinikum der Universität München, Munich: J.R. Bogner, I. Ott; 
Klinikum Dortmund GmbH, Dortmund: M. Hower, C. Bachmann; Medizinische Hochschule Hannover, 
Hannover: M. Stoll, R. Bieder; Medizinische Universitätsklinik - Bonn, Bonn: J. Rockstroh, B. Becker; 
Universitätsklinikum Düsseldorf, Düsseldorf: B. Jensen, C. Feind; Universitätsklinikum Erlangen, 
Erlangen: E. Harrer, T. Harrer; Universitätsklinikum Essen, Essen: S. Esser, H. Wiehler; 
Universitätsklinikum Heidelberg, Heidelberg: M. Hartmann, R. Röger; Universitätsklinikum Regensburg, 
Regensburg: B. Salzberger, E. Jäger; Universitätsklinikum Würzburg, Würzburg: H. Klinker, G. Mark; 
Universitätsklinikum, Hamburg-Eppendorf: J. van Lunzen, N. Zerche; German SSC, Johann Wolfgang 
Goethe - University Hospital, Frankfurt: V. Müller, K. Tillman.   
 
Greece (G. Touloumi, n=101): AHEPA University Hospital, Thessaloniki Central Macedonia: S. 
Metallidis, O. Tsachouridou; Attikon University General Hospital, Athens: A. Papadopoulos, K. 
Protopapas; Evangelismos General Hospital, Athens: A. Skoutelis, V. Papastamopoulos; Hippokration 
University General Hospital of Athens, Athens: H. Sambatakou, I. Mariolis; Korgialenio-Benakio 
Hellenic Red Cross, Athens: M. K. Lazanas, M. Chini; Syngros Hospital, Athens: S. Kourkounti, V. 
Paparizos; Greek SCC, National Kapodistrian University of Athens, Athens: G. Touloumi, V. Gioukari, 
O. Anagnostou.  
 
India (n=91): Institute of Infectious Diseases, Pune Maharashtra: A. Chitalikar, S. Pujari; YRGCARE 
Medical Centre VHS, Chennai CRS: F. Beulah, N. Kumarasamy, S. Poongulali.  
 
Ireland (P. Mallon, n=7): Mater Misericordiae University Hospital, Dublin: P. Mallon, P. McGettrick.  
 
Israel (E. Kedem, n=28): Rambam Medical Center, Haifa: E. Kedem, S. Pollack; Tel Aviv Sourasky 
Medical Center, Tel Aviv: D. Turner.  
 
Italy (G. Tambussi, n=33): Lazzaro Spallanzani IRCSS, Rome: A. Antinori, R. Libertone; Ospedale San 
Raffaele S.r.l., Milan: G. Tambussi, S. Nozza, M.R. Parisi.  
 
Luxembourg (T. Staub, n=5): Centre Hospitalier de Luxembourg, Luxembourg: T. Staub, C. Lieunard.  
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Malaysia (n=18): University Malaya Medical Centre, Kuala Lumpur: R.I.S.R. Azwa.  
 
Mali (S. Dao, n=41): SEREFO/ CESAC Mali, Bamako, Bamako: B. Baya, M. Cissé, D. Goita.  
 
Mexico (n=48): INCMNSZ (Instituto Nacional de Ciencias Médicas y Nutrición), Tlalpan D.F.: J. Sierra-
Madero, M.E. Zghaib.  
 
Morocco (K.M. El Filali, n=44): University Hospital Centre Ibn Rochd, Casablanca: K.M. El Filali, I. 
Erradey, H. Himmich.  
 
Nigeria (n=50): Institute of Human Virology-Nigeria (IHVN), Garki, Abuja FCT: E. Ekong, N. Eriobu.  
 
Norway (V. Ormaasen, n=15): Oslo University Hospital, Ulleval, Oslo: V. Ormaasen, L. Skeie.  
 
Peru (A. La Rosa, n=215): Hospital Nacional Edgardo Rebagliati Martins, Lima, Lima: M. Espichan 
Gambirazzio, F. Mendo Urbina; Hospital Nacional Guillermo Almenara Irigoyen, Lima, Lima: R. Salazar 
Castro, J. Vega Bazalar; IMPACTA Salud y Educación, Lima, Lima: M.E. Guevara, R. Infante, J. 
Sanchez, M. Sanchez; IMPACTA San Miguel, Lima, Lima: R. Chinchay, J.R. Lama, M. Sanchez; Via 
Libre, Lima, Lima: E.C. Agurto, R. Ayarza, J.A. Hidalgo.  
 
Poland (A.J. Horban, n=68): EMC Instytut Medyczny SA, Wroclaw: B. Knysz, A. Szymczak; 
Uniwersytecki Szpital Kliniczny, Bialystok: R. Flisiak, A. Grzeszczuk; Wojewodzki Szpital Zakazny, 
Warsaw: A.J. Horban, E. Bakowska, A. Ignatowska.  
 
Portugal (L. Caldeira, n=67): Hospital Curry Cabral, Lisbon: F. Maltez, S. Lino; Hospital de Egas Moniz, 
Lisbon: K. Mansinho, T. Bapista; Hospital de Santa Maria, Lisbon: M. Doroana, A. Sequeira, L. Caldeira; 
Hospital Joaquim Urbano, Oporto: J. Mendez, R.S.E. Castro.  
 
South Africa (R. Wood, n=518): 1 Military Hospital, Pretoria Gauteng: S.A. Pitsi; Desmond Tutu HIV 
Centre - Cape Town, Cape Town, Western Province: R. Kaplan, N. Killa, C. Orrell, M. Rattley; Durban 
International Clinical Research Site, Durban, KwaZulu Natal: U.G. Lalloo, R. Mngqibisa, S. Pillay; 
Durban International Clinical Research Site WWH, Durban, KwaZulu Natal: J. Govender, M. John; 
University of Witwatersrand, Johannesburg, Gauteng: S. Badal-Faesen, N. Mwelase, M. Rassool.  
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Spain (J.R. Arribas, n=234): Complejo Hospitalario Xeral Cies, Vigo Pontevedra: A.O. Hermida, F. 
Warncke; Hospital Clínic de Barcelona, Barcelona: J.M. Gatell, A. Gonzalez; Hospital Clínico San 
Carlos, Madrid: V. Estrada, M. Rodrigo; Hospital de la Santa Creu i Sant Pau, Barcelona: P. Domingo, 
M. Gutierrez; Hospital del Mar, Barcelona: H.J. Knobel, A. Gonzalez; Hospital La Paz, Madrid: J.R. 
Arribas, M. Montes Ramirez; Hospital La Princesa, Internal Medicine and Infectious Disease Service 
CRS, Madrid: I. de los Santo Gil, J. Sanz Sanz; Hospital Universitari Germans Trias i Pujol, Badalona: B. 
Clotet, J.M. Llibre, P. Cobarsi; Hospital Universitari Mutua Terrassa, Terrassa Barcelona: D. Dalmau, C. 
Badia; Hospital Universitario Doce de Octubre, Madrid: R. Rubio, M.M. del Amo; Hospital Universitario 
Príncipe de Asturias, Alcala de Henares Madrid: J. Sanz Moreno; Hospital Universitario y Politécnico La 
Fe, Valencia: J. López Aldeguer, S. Cuellar; Spanish SSC, Acoiba, Madrid: P. López, B. Portas, P. 
Herrero.  
 
Sweden (M. Gisslén, n=2): Sahlgrenska University Hospital, Sweden: M. Gisslén, L. Johansson; Skåne 
University Hospital, Malmö: C. Håkangård, K. Törqvist.  
 
Switzerland (H. Furrer, n=31): Bern University Hospital, Bern: H. Furrer, A. Rauch; Unite VIH/SIDA 
Genèva, Genèva: A.L. Calmy, B. Hirschel (retd), T Lecompte; University Hospital Basel, Basel: M. 
Stoeckle; University Hospital Zurich, Zürich: N. Muller, M. Rizo-Oberholzer; Swiss SCC, Bern 
University Hospital, Bern: H. Furrer, C. Bruelisauer, A. Christen, M. Lacalamita.  
 
Thailand (K. Ruxrungtham, n=248): Bamrasnaradura Infections Diseases Institute, Nonthaburi: W. 
Prasithsirikul, S. Thongyen; Chiangrai Prachanukroh Hospital, Chiang Rai: P. Kantipong, S. Khusuwan; 
Chonburi Regional Hospital, Chonburi: C. Bowonwatanuwong, U. Ampunpong; Chulalongkorn 
University Hospital, Bangkok: K. Ruxrungtham, A. Avihingsanon, W. Thiansanguankul; Khon Kaen 
University, Srinagarind Hospital, Khon Kaen: P. Chetchotisakd, P. Motsikapun, S. Anunnatsari; 
Ramathibodi Hospital, Bangkok: S. Kiertiburanakul, N. Sanmeema; Research Institute for Health 
Sciences (RIHES), Chiang Mai: K. Supparatpinyo, P. Sugandhavesa; Sanpatong Hospital, Chiang Mai: 
V. Klinbuayaem, Y. Siriwarothai; Siriraj Hospital, Bangkok Noi: W. Ratanasuwan, T Anekthananon; 
Thai SCC, The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok: W. 
Harnnapachewin, T. Jupimai, P. Rerksirikul. 
 
Uganda (P. Mugyenyi, n=349): Joint Clinical Research Center (JCRC), Kampala: P. Mugyenyi, C. Kityo, 
H. Mugerwa; MRC/UVRI Research Unit on AIDS, Entebbe: P. Munderi, B. Kikaire, J. Lutaakome; 
MRC/UVRI Research Unit on AIDS, Masaka – satellite site: Z. Anywaine.  
 
United Kingdom (M.A. Johnson, n=339): Barts Health NHS Trust, London: C. Orkin, J. Hand; Belfast 
Health and Social Care Trust (RVH), Belfast Northern Ireland: C. Emerson, S. McKernan; Birmingham 
Heartlands Hospital, Birmingham West Midlands: D. White, C. Stretton; Brighton and Sussex University 
Hospitals NHS Trust, Brighton East Sussex: M. Fisher, A. Clarke, A. Bexley; Chelsea and Westminster 
Hospital, London: B. Gazzard, C. Higgs, A. Jackson; Coventry and Warwickshire NHS partnership Trust, 
Coventry West Midlands: S. Das, A. Sahota; Gloucestershire Royal Hospital, Gloucester: A. de Burgh-
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Thomas, I. Karunaratne; Guy's and St.Thomas' NHS Foundation Trust, London: J. Fox, J.M. Tiraboschi; 
Imperial College Healthcare NHS Trust, London: A. Winston, B. Mora-Peris; Leicester Royal Infirmary, 
Leicester Leicestershire: M.J. Wiselka, L. Mashonganyika; Lewisham and Greenwich NHS Trust, 
London: S. Kegg, T. Moussaoui; North Manchester General Hospital, Manchester: E. Wilkins, Y. 
Clowes; Queen Elizabeth Hospital Birmingham, Birmingham West Midlands: J. Ross, J. Harding; Royal 
Berkshire Hospital, Reading Berkshire: F. Chen, S. Lynch; Royal Bournemouth Hospital, Bournemouth 
Dorset: E. Herieka, J. Ablorde; Royal Free London NHS Foundation Trust, London: M.A. Johnson, M. 
Tyrer, M. Youle; Sheffield Teaching Hospital NHS Foundation Trust, Sheffield South Yorkshire: D. 
Dockrell, C. Bowman; Southmead Hospital, Bristol: M. Gompels, L. Jennings; St. George's Healthcare 
NHS Trust, London: P. Hay, O. Okolo; The James Cook University Hospital, Middlesbrough Cleveland: 
D.R. Chadwick, P. Lambert; University College London Medical School, London: I. Williams, A. Ashraf.  
 
United States (K. Henry, n=507): Adult Clinical Research Center, Newark, NJ: M. Paez-Quinde, S. 
Swaminathan; Boston University Medical Center, Boston, MA: I. Bica, M. Sullivan; Bronx-Lebanon 
Hospital Center, Bronx, NY: R.B. Cindrich, L.M. Vasco; Community Research Initiative of New 
England, Boston, MA: J. Green, H.B. Olivet; Cooper University Hospital, Camden, NJ: J. Baxter, Y. 
Smith; Cornell CRS, New York, NY: V. Hughes, T. Wilkin; Denver Public Health, Denver, CO: E.M. 
Gardner, J. Scott; Duke University, Durham, NC: J. Granholm, N. Thielman; Florida Department of 
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